文献简介

出版社:Biomedicine & Pharmacotherapy

作  者:Bhakti Sawant, Tabassum Khan

编  号:

关键字:Candidiasis;Antifungals;Echinocandins;Novel drug delivery systems

年  份:2017   点击量:142

文献摘要 全文翻译

Candidiasis is a fungal infection caused by yeasts that belong to the genus Candida. There are over twenty species of Candida yeasts that can cause infection in humans, the most common of which is Candida albicans. Candida yeasts normally reside in the intestinal tract and can be found on mucous membranes and skin without causing infection; however, overgrowth of these organisms can cause symptoms to develop. Presence of other diseases that compromises the patient’s immunity makes it more difficult to treat. Candidiasis is majorly divided into superficial infections (oral or vaginal) and systemic infections, also known as invasive candidiasis. The conventional therapeutic modalities used to treat candidiasis are associated with several side effects that limits the dose and dosing frequency. Development of novel drug delivery systems for reduction in dose and alleviation of side effects is an important strategy to improve the clinical efficacy and patient acceptability. This review gives a bird’s eye view of the classification and current therapeutic regime of candidiasis. It presents the varied types of drug delivery systems that have been exploited for delivery of antifungal agents with measurable benefits. It also touches upon echinocandins a relatively new class of drugs that are amenable for translation into novel dosage forms with application against biofilm producing and fluconazole resistant strains contributing to a better therapeutic management of candidiasis.

念珠菌病是一种由念珠菌酵母引起的真菌感染病。20余种念珠菌可引起人类感染,其中最常见的是白色念珠菌。白色念珠菌通常定植于肠道中,也可见于粘膜和皮肤而不引起感染;然而,这些病原菌的过度生长可导致症状发展。损害患者免疫力的其他疾病的存在使得治疗更困难。念珠菌病主要分为体表感染(口腔或阴道)和全身性感染,也称为侵袭性念珠菌病。用于念珠菌病治疗的常规治疗方法存在若干副作用,限制了用药剂量和用药频率。开发新型给药系统减少用药剂量和减轻副作用是提高临床疗效和患者可接受性的重要策略。本文概述了念珠菌病的分类和治疗现状,介绍了各种类型的给药系统,且这些系统已被用于输送抗真菌药物并带来了可衡量的益处。本文还涉及棘白菌素类(一种相对较新的药物),可转化为新型剂型,用于抗生物膜产生和氟康唑耐药菌株,从而有助于更好地治疗念珠菌病。